Alembic gets USFDA OK for Prucalopride, but $100M market faces competition
The approval adds a chronic-constipation generic to Alembic’s US pipeline, but generic competition and the company's scale make the near-term financial impact negligible.
— 9 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- USFDA final approval for generic Prucalopride tablets, 1 mg and 2 mg, on 28 July 2026.
- Cumulative ANDA approvals reach 245 (225 final, 20 tentative).
- US generics revenue was ₹2,206 crore in FY26, up 13% YoY.
Why this matters
At $100M, Prucalopride is a small market with multiple competitors. For a company generating ₹7,345 crore in total revenue, this approval alone won't move the needle. Alembic's larger near-term catalysts remain the Olaparib and Binimetinib tentative approvals, which target markets worth $1.4B and $259M respectively.
What we're watching
- Timeline for final approval of Olaparib tablets (partnered with NATCO).
- Resolution status of the USFDA warning letter on the ICF facility.
- Any further large-market generic launches in the pipeline.
The full read
Alembic Pharmaceuticals secured final USFDA approval for generic Prucalopride tablets, adding a chronic-constipation treatment to its US generics portfolio. The US market is $100M — but it's already generic, limiting pricing power. For a company with ₹7,345 crore in annual revenue and ₹2,206 crore from US generics alone, this is one of many routine ANDA approvals. The real catalysts are bigger: the tentative nods for Olaparib ($1.4B market) and Binimetinib ($259M) , plus resolution of the warning letter at its ICF facility. This approval keeps the pipeline flowing, but it's not an event that changes the story.
Questions answered
- What is Prucalopride used for?
- It treats chronic idiopathic constipation. The generic version will compete with the brand Motegrity.
- How big is the US market for Prucalopride?
- According to IQVIA, the US market was about $100 million for the twelve months ending March 2026.
- Will this approval significantly impact Alembic's revenue?
- No. With total revenue of ₹7,345 crore and US generics at ₹2,206 crore, a $100M market that is already competitive will have immaterial near-term financial impact.
- What is Alembic's track record with USFDA approvals?
- Alembic has 245 cumulative ANDA approvals (225 final, 20 tentative) from the USFDA.
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 28 Jul 2026 · 1:26 PM IST Alembic gets USFDA OK for Prucalopride, but $100M market faces competition
- 10d ago Alembic's partner lands tentative OK for $1.4B cancer drug
- 15d ago Alembic gets USFDA warning letter over ICF; facility unimpacted
- 39d ago Alembic eyes $259M cancer market with tentative US nod for Binimetinib
- 46d ago Alembic gets USFDA nod for generic Retin-A — but market is small